Home > Boards > US OTC > Medical - Drugs >

ScripsAmerica Inc. (SCRCQ)

Add SCRCQ Price Alert      Hide Sticky   Hide Intro
Moderator: pennystock_es, Huggy Bear
Search This Board: 
Last Post: 5/14/2019 9:09:27 AM - Followers: 169 - Board type: Free - Posts Today: 0

ScripsAmerica (SCRC -OTC BB ) provides a strong low cost system of broad base US national marketing, sales and distribution of generic Rx, branded Rx, OTC, nutraceuticals, and oral delivery OTC pharmaceuticals through mass merchants, super markets, chain drug stores, independent drug stores, hospitals, long term care, HMO’s, home health care, clinics, PBM’s, State and Federal Government (Department of Veterans Affairs, Department of Defense).

This strong marketing platform can provide a launch pad for immediately introducing ANDAs for any global company. “Pull Through” network of the Company results in strong customer retention, low cost and access to wide customer base.

The Company has strong relationships with local customers and deep understanding of and ability to serve customer needs. These relationships with ScripsAmerica will allow the Company to acquire asubstantial shelf space for its products in very short span of time.

The Company caters to a large base of customers without carrying substantial inventory. This demonstrates ScripsAmerica’s ability of flawless execution of management in a pure generic market. Going forward, with the increase in the revenue and customer base, the Company is focused on ensuring strict control on its inventory, at the same time achieving minimum turnaround time.

Some people may wish to better understand the economically intelligent practice of generic substitution for branded drugs. We've put this section together to assist in this endeavor. It is taken primarily from the US FDA Office of Generic Drugs website (http://www.fda.gov/cder/ogd) which contains a wealth of additional information for those truly inquisitive minds.


The GphA site (http://www.gphaonline.org) is another excellent source where visitors can learn that "generic drugs contain the same active ingredients, in the very same strength, as brand-name drugs." Stated simply here, "When a medicine is first developed, the pharmaceutical company that discovers and markets it receives a patent on its new drug. The patent usually lasts for 20 years, to give the originating company a chance to recoup its research investment. After the patent expires, a generic version of the drug may become available. Generics are marketed under the drug's chemical, or "generic," name and meet the same U.S. Food and Drug Administration (FDA) quality and effectiveness standards as the original."

 According to the US FDA, a generic drug is identical (defined as bio-equivalent) to a brand name drug in dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use. Although generic drugs' active ingredients are chemically identical to and equally as effective as their branded counterparts, they are typically sold at substantial discounts from the branded price. According to the Congressional Budget Office, generic drugs save consumers an estimated $8-$10 billion a year at retail pharmacies. Even more billions are saved when hospitals use generics.

 To Gain FDA approval a generic drug must:
•Contain the same active ingredients as the innovator drug (inactive ingredients may vary)
•Be identical in strength, dosage form and route of administration
•Have the same use indications
•Be bio-equivalent
•Meet the same batch requirements for identity, strength, purity and quality
•Be manufactured under the same strict standards of FDA's good manufacturing practice regulations required for innovator products.
On its site, the GphA states, "With every prescription that you have filled with a generic, you get the same medicine as the brand, with the same quality and same result, but at a much lower cost." So, at the end of the day, generics offer a smart and affordable alternative to branded drug therapies. To learn more, visit one of these excellent sites:



Robert Schneiderman, Chief Executive Officer, Founding Partner 
Mr. Schneiderman has an extensive background of accomplishments. His experience includes using his established network to facilitate the financing of public and non public companies and assisting with mergers and acquisitions. His clients have included StarMed Group Inc., Medical Wellness Inc., Direct Pharmacy Services Inc., Aquantum Pharmaceuticals Inc., Coral Water Inc., Radius WellCare Inc., Axis Technology Inc., and Global Resources Inc. He has been involved with marketing and consulting on a vast array of projects. These projects have included expansion of clients’ customer base via product development, placement into mass retail, development of marketing programs, and effectively establishing and maintaining communications between all involved parties.  
Mr. Schneiderman brings to ScripsAmerica expertise in implementing marketing strategies, developing advertising-media programs, project management, structuring of operational systems, facilitation of client needs, procedures, expanding marketing channels, liaison between marketing channels-services and clients, as well as contract negotiations. 
Mr. Schneiderman has had personnel, operations, financial management and supervisory experience for 32 years as CEO of a prominent Philadelphia recruiting firm. In addition, he has served as committee chairman for charity and community service organizations guiding, advising, recruiting and motivating volunteers and has engaged in hands-on supervision and activity in the areas of fundraising, gala events, special event planning, social event planning, enhancement of membership recruitment procedures, writing of newsletter articles, and speeches.  Mr. Schneiderman earned a B.S. in Business from Temple University.
Jeffrey Andrews, Chief Financial Officer
A creative, results-oriented problem solver with a background in financial accounting, Mr. Andrews has served companies in the manufacturing, distribution, technology, consulting, construction, and service industries.  His professional experience includes tenure as Chief Financial Officer for Global Resource Corporation, Judge Information Management Solutions, and The Judge Group; Controller of Encapsulation Systems, Goodwin Pumps of America, Morris Wheeler & Co., and Mater Burt Co.; Audit Manager of Stockton Bates/Gold & Co., C.P.A.; and as Manager of Ernst & Young’s Special Services Group.
After joining ScripsAmerica in September 2010, Mr. Andrews took responsibility for the overall financial management of the Company, financial reporting and transparency, and for corporate functions including controller, treasury, investor relations, long-range planning, and corporate and strategic development.  Mr. Andrews earned a B.S. in Accounting from Villanova University, is a Certified Public Accountant in the Commonwealth of Pennsylvania, and a member of both the American Institute and the Pennsylvania Institute of Certified Public Accountants.

Wayne Ambler, Director of Marketing
Accomplished, sales and marketing professional with over two decades experience in the competitive store brand OTC health and wellness marketplace. An articulate, reliable, and proven revenue producer adept at assessing prospects capabilities and strengths to create new marketing opportunities for expansion of existing product offerings while pioneering client new growth.  

Professional services include direct sales coverage and broker management  for store brand OTC companies in all classes of retail trade (FDM) 
Assists in product selection, brand marketing, promotional activities, sales tools and website development, specializing in the pharmaceutical industry.  

Featured Products and Applications

RapiMed Product Line                             
In light of the fact that the ODT market is growing significantly, driven by patient demand, rapid melt technology, provides pharmaceutical companies with the much-needed opportunity for product line extensions for a wide variety of drugs. ScripsAmerica sees a significant opportunity as a contract developer of Quickmelt technology embedded in RapiMed specialty pharmaceuticals.  
In March 2010, ScripsAmerica entered into a product development, manufacturing, and supply agreement for Acetaminophen 80mg and 160mg orally disintegrating rapid dissolve tablets under which its partner will develop and supply the product, while ScripsAmerica will fund all development costs and own the final product. 
The Company’s initial focus is on Pediatric analgesic 80mg and 160mg orally disintegrating rapid dissolve tablets, which are under development with a market rollout scheduled for Q2 2013. The 80mg and 160mg dosing strength will be particularly applicable to children to solvecommon overdosing or under dosing issues that 2-11-year-olds tend to experience when taking liquid pain relievers or fever reducers in doses intended for adults.
Safely administering liquids such as Children’s Tylenol Suspension to children requires precise dosage measurement in increments of half a teaspoon, depending on the child’s weight or age. Inadvertent overdosing – whether by an adult’s error or perhaps a child’s self-administration - may lead to severe liver damage and requires immediate medical attention even in the absence of signs or symptoms. Conversely, ODTs such as ScripsAmerica’s Pediatric RapiMed represent a precise, standardized dose in the form of discrete, easy-to-count, individually blister-packaged tablets, thereby reducing the probability of human error while the drug is being administered. Finally, the taste of ODTs can easily be tailored to appeal to children, using a variety of flavored coatings.
ScripsAmerica’s Pediatric “RapiMed” will compete with other children’s analgesic products, such as Johnson & Johnson’s Children’s Tylenol Suspension Liquid and Children’s Tylenol Meltaways, Novartis’ Triaminic Fever Reducer Pain Reliever, and Perrigo’s Junior Strength Non-Aspirin Suspension Liquids & Drugs. According to Euromonitor International’s research, J&J’s Children’s Tylenol sales represented 23% of global and 76% of U.S. retail value sales in child-specific analgesics. Global sales were valued at $695 million in 2009. 
ScripsAmerica anticipates project completion with market rollout scheduled for 2013.
RapiMed formulation is compatible for use in the development of Oral Delivery Technology products to treat Migraines, Sleep Deprivation, Allergies, and Vitamin Deficiencies
 more lat night 

Ticker Symbol: SCRCQ
Outstanding Shares: 137M in which just Three owners hold 79% of Entire OS!
Floating Shares: 80M in which only a few millions shares available for trading!

Shareholders:103  Funding to Date:2.5 Mil

Preferred Convertible: $1.1 mil @ .175
Convertible Debt: 975k @ .25 
Other: 453K @ 4 Year Term
Shares Structure: Delaware Corp

Historic Chart

Updated Date: 2019-03-19T14:28:17Z

Creation Date: 2008-04-29T23:35:56Z
Registrar Registration Expiration Date: 2020-03-18T11:59:59Z
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#24668  Sticky Note ATTENTION! Key Shares-Structure (SS) Updating from the TA: Value_Investor 04/17/19 12:19:36 PM
#24700   The website works $SCRCQ : http://scripsamerica.com/ Updated Date: 2019-03-19T14:28:17Z pennystock_es 05/14/19 09:09:27 AM
#24699   12 x 14 lets Go $SCRCQ pennystock_es 05/13/19 03:50:30 PM
#24698   The next bid is 0.0005 ! I'm wondering if Value_Investor 05/10/19 04:40:03 PM
#24697   SCRCQ is down 33.33% so far! At 0.0009 Value_Investor 05/07/19 11:58:35 AM
#24696   Nice to see SCRCQ hit 0.0015 again! 0.0011 Value_Investor 05/03/19 07:28:30 PM
#24695   $SCRCQ 56% BUY https://www.barchart.com/stocks/quotes/SCRCQ/opinion pennystock_es 05/02/19 02:33:45 AM
#24694   Time to go bananas BigGainsBigBens 05/01/19 10:04:09 PM
#24693   Last document presented in 2016 a form12-15, something pennystock_es 05/01/19 02:39:38 PM
#24692   Can this company $SCRCQ be the target of pennystock_es 05/01/19 02:20:55 PM
#24691   Where can I check the OS has a pennystock_es 05/01/19 12:31:47 PM
#24690   Nice to see SCRCQ hit the strong Resistance Value_Investor 05/01/19 12:24:27 PM
#24689   $SCRCQ 12 x 13 is HOT pennystock_es 05/01/19 11:01:22 AM
#24688   Nice to see 0.0008 x 0.0009 now! We Value_Investor 04/30/19 04:08:32 PM
#24687   0.0007 x 0.0009 now. LOL, do you have Value_Investor 04/29/19 12:26:02 PM
#24686   Do you have the link to consult? pennystock_es 04/26/19 04:18:50 PM
#24685   They both are not Nevada companies! Check with Value_Investor 04/26/19 04:12:53 PM
#24684   In which web I can see the number pennystock_es 04/26/19 03:55:35 PM
#24683   Wrong Info., my friend --- the OS was Value_Investor 04/26/19 01:19:29 PM
#24682   $SCRCQ is starting to get some eyes from pennystock_es 04/26/19 09:17:29 AM
#24681   $SCRCQ SECURITY DETAILS pennystock_es 04/23/19 02:48:31 PM
#24680   0.0007 x 0.0011 now. I'm wondering why those Value_Investor 04/23/19 12:44:46 PM
#24679   775K-0.0007 x 527K-0.0012 now. The next ask is Value_Investor 04/22/19 10:14:30 AM
#24678   SCRCQ is up 11.11% at $0.0010 or $141K Value_Investor 04/21/19 03:37:30 PM
#24677   Do you have the link? is active ? pennystock_es 04/20/19 01:27:39 AM
#24676   Do you have the link? is active ? pennystock_es 04/20/19 01:27:27 AM
#24675   Because SCRCQ is not a Nevada company. It Value_Investor 04/19/19 09:08:49 PM
#24674   Yes, I wish to see those 600K shares Value_Investor 04/18/19 10:01:02 AM
#24673   Strong demand $SCRCQ at 0.0010 and out offer pennystock_es 04/18/19 09:53:07 AM
#24672   I do not locate ScripsAmerica on Nevada's official pennystock_es 04/17/19 02:26:41 PM
#24671   SCRCQ is down 10% so far from today's Value_Investor 04/17/19 01:48:03 PM
#24670   Does $SCRCQ have any assets or patents left? pennystock_es 04/17/19 12:27:21 PM
#24669   This is very hot $SCRCQ ... to others pennystock_es 04/17/19 12:22:22 PM
#24668   ATTENTION! Key Shares-Structure (SS) Updating from the TA: Value_Investor 04/17/19 12:19:36 PM
#24667   there is hardly any volume $SCRCQ, something happens pennystock_es 04/17/19 12:09:46 PM
#24666   BUY $SCRCQ ¡¡ pennystock_es 04/17/19 07:31:51 AM
#24665   yes Bid Price 0,0012 ¡¡¡ pennystock_es 04/16/19 12:40:15 PM
#24664   0.0012 x 0.0013 now. The bid was raised Value_Investor 04/16/19 12:27:14 PM
#24663   0.0009 x 0.0013 now. No more 0.0014 ~ Value_Investor 04/15/19 10:55:44 AM
#24662   Yes ¡¡ Lets GO ¡¡¡ pennystock_es 04/13/19 03:28:23 AM
#24661   Is it time to slap out 0.0014s ~ Value_Investor 04/12/19 02:48:49 PM
#24660   thanks for the information something is cooking $SCRCQ pennystock_es 04/11/19 01:58:51 PM
#24659   To all our SCRCQ shareholders: Who is going Value_Investor 04/11/19 01:17:16 PM
#24658   sorry, did you refer to the company's "ceo" pennystock_es 04/08/19 04:22:45 PM
#24657   135K-0.0007 x 537K-0.0013 now. SCRCQ declined over 22.22% Value_Investor 04/08/19 10:52:38 AM
#24656   I think this will be great, as always pennystock_es 04/08/19 09:41:25 AM
#24655   It seems 0.0013 is the Lowest price to Value_Investor 04/07/19 06:06:56 PM
#24654   Nice to see 0.0009 x 0.0013 again! Hopefully Value_Investor 04/05/19 04:17:58 PM
#24653   10K-0.0008 x 10K-0.0009 now. The next two asks Value_Investor 04/05/19 11:12:48 AM
#24652   10K-0.0008 x 10K- 0.0010 now. The ask was as Value_Investor 04/04/19 01:28:22 PM
#24651   YAW! 0.0007 x 0.0012 now and the next Value_Investor 04/04/19 10:42:18 AM